FLEMINGTON, N.J., March 30, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the fourth quarter and full year of 2015 and provided an update on recent clinical developments for its lead compound, onapristone.
Fourth Quarter 2015 and Recent Highlights
* In January 2016, Arno completed an equity financing of approximately $7.4 million, including approximately $2.1 million from the automatic conversion of outstanding promissory notes originally issued in October 2015.
